Please ensure Javascript is enabled for purposes of website accessibility

Why Ignyta, Inc. Stock Is Soaring Today

By George Budwell - Dec 22, 2017 at 9:15AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Roche takes out U.S. cancer drug specialist Ignyta Inc. for $1.7 billion.

What happened

Ignyta, Inc. (NASDAQ: RXDX) shareholders are getting an early Christmas present today after the cancer giant Roche (RHHBY 1.39%) decided to scoop up the company for $1.7 billion. According to the press release, Roche agreed to pay $27 per share for the cancer specialist, representing a 74% premium compared to where Ignyta's shares ended yesterday. The deal is expected to close in the first half of 2018. Ignyta stock is up by 72.67% in pre-market trading in response to this news.    

A rocket taking off.

Image source: Getty Images.

So what

A nearly $2 billion deal for a clinical-stage biotech might seem like a lot, but this buyout could very well turn out to be a bargain for Roche. Despite the lack of a true late-stage clinical candidate, Ignyta's pipeline of early- to mid-stage cancer drugs are on the absolute cutting edge of their field. Long story short, this deal should significantly advance Roche's goal of becoming a leader in precision anti-cancer therapies

Now what

Ignyta's most advanced clinical candidate, entrectinib, is presently in a mid-stage study for a wide range of tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. The key takeaway is that some industry insiders think that this trial could lead to an accelerated approval for multiple indications by as early as 2019.

If this line holds, entrectinib should become a blockbuster product in short order -- underscoring the bargain aspect of this deal. Even if entrectinib fails, though, Ignyta's promising lineup of earlier-stage clinical candidates could still make this deal a winner for Roche. Stated simply, Roche is taking on some risk by gobbling up Ignyta fairly early in its clinical lifecycle, but the price also seems to adequately reflect that risk. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Roche Holding AG Stock Quote
Roche Holding AG
RHHBY
$42.22 (1.39%) $0.58

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.